These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 33601493)

  • 1. [Treatment of ALK negative metastatic inflammatory myofibroblastic tumor by combination of pembrolizumab and anlotinib: a case report].
    Li XS; Li XF; Jin LF; Zhao Y; Shen WZ
    Zhonghua Zhong Liu Za Zhi; 2021 Feb; 43(2):240-242. PubMed ID: 33601493
    [No Abstract]   [Full Text] [Related]  

  • 2. Pembrolizumab enhances the anti-pancreatic cancer activity of anlotinib.
    Mafei K; Shengyuan X; Jieqiong S
    Asian J Surg; 2022 Mar; 45(3):881-882. PubMed ID: 34998639
    [No Abstract]   [Full Text] [Related]  

  • 3. Inflammatory myofibroblastic tumors of the lung carrying a chimeric A2M-ALK gene: report of 2 infantile cases and review of the differential diagnosis of infantile pulmonary lesions.
    Tanaka M; Kohashi K; Kushitani K; Yoshida M; Kurihara S; Kawashima M; Ueda Y; Souzaki R; Kinoshita Y; Oda Y; Takeshima Y; Hiyama E; Taguchi T; Tanaka Y
    Hum Pathol; 2017 Aug; 66():177-182. PubMed ID: 28705706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory Myofibroblastic Tumor of the Tongue. Report of a Pediatric Case and Review of the Literature.
    Caporalini C; Moscardi S; Tamburini A; Pierossi N; Di Maurizio M; Buccoliero AM
    Fetal Pediatr Pathol; 2018 Apr; 37(2):117-125. PubMed ID: 29336647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion.
    Subbiah V; McMahon C; Patel S; Zinner R; Silva EG; Elvin JA; Subbiah IM; Ohaji C; Ganeshan DM; Anand D; Levenback CF; Berry J; Brennan T; Chmielecki J; Chalmers ZR; Mayfield J; Miller VA; Stephens PJ; Ross JS; Ali SM
    J Hematol Oncol; 2015 Jun; 8():66. PubMed ID: 26062823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALK-1 protein expression and ALK gene rearrangements aid in the diagnosis of inflammatory myofibroblastic tumors of the female genital tract.
    Fuehrer NE; Keeney GL; Ketterling RP; Knudson RA; Bell DA
    Arch Pathol Lab Med; 2012 Jun; 136(6):623-6. PubMed ID: 22646268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A successful pembrolizumab treatment case of lung adenocarcinoma after becoming resistant to ALK-TKI treatment due to G1202R mutation.
    Shimada M; Tamura A; Yokosuka K; Kusaka K; Matsui H; Nagai H; Ohta K
    Respir Investig; 2018 Jul; 56(4):365-368. PubMed ID: 30008296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.
    Zhou AP; Bai Y; Song Y; Luo H; Ren XB; Wang X; Shi B; Fu C; Cheng Y; Liu J; Qin S; Li J; Li H; Bai X; Ye D; Wang J; Ma J
    Oncologist; 2019 Aug; 24(8):e702-e708. PubMed ID: 30902918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel fusion of HNRNPA1-ALK in inflammatory myofibroblastic tumor of urinary bladder.
    Inamura K; Kobayashi M; Nagano H; Sugiura Y; Ogawa M; Masuda H; Yonese J; Ishikawa Y
    Hum Pathol; 2017 Nov; 69():96-100. PubMed ID: 28504207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALK-positive gastric inflammatory myofibroblastic tumor in an adult with familial adenomatous polyposis and diffuse fundic polyposis.
    Fan J; Huang B; Yang X; Yang M; He J; Nie X
    Diagn Pathol; 2017 Sep; 12(1):68. PubMed ID: 28923119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
    Parker BM; Parker JV; Lymperopoulos A; Konda V
    J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
    Xie C; Wan X; Quan H; Zheng M; Fu L; Li Y; Lou L
    Cancer Sci; 2018 Apr; 109(4):1207-1219. PubMed ID: 29446853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelioid inflammatory myofibroblastic sarcoma: a clinicopathological, immunohistochemical and molecular cytogenetic analysis of five additional cases and review of the literature.
    Yu L; Liu J; Lao IW; Luo Z; Wang J
    Diagn Pathol; 2016 Jul; 11(1):67. PubMed ID: 27460384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
    Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
    Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anlotinib: First Global Approval.
    Syed YY
    Drugs; 2018 Jul; 78(10):1057-1062. PubMed ID: 29943374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALK-positive inflammatory myofibroblastic tumor harboring ALK gene rearrangement, occurring after allogeneic stem cell transplant in an adult male.
    Vroobel K; Judson I; Dainton M; McCormick A; Fisher C; Thway K
    Pathol Res Pract; 2016 Aug; 212(8):743-6. PubMed ID: 27155927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors.
    Sun Y; Niu W; Du F; Du C; Li S; Wang J; Li L; Wang F; Hao Y; Li C; Chi Y
    J Hematol Oncol; 2016 Oct; 9(1):105. PubMed ID: 27716285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.
    Yamamoto H; Yoshida A; Taguchi K; Kohashi K; Hatanaka Y; Yamashita A; Mori D; Oda Y
    Histopathology; 2016 Jul; 69(1):72-83. PubMed ID: 26647767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anlotinib in combination with pembrolizumab for low-grade myofibroblastic sarcoma of the pancreas: A case report.
    Wu RT; Zhang JC; Fang CN; Qi XY; Qiao JF; Li P; Su L
    World J Clin Cases; 2023 Dec; 11(35):8385-8391. PubMed ID: 38130609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study.
    Cook JR; Dehner LP; Collins MH; Ma Z; Morris SW; Coffin CM; Hill DA
    Am J Surg Pathol; 2001 Nov; 25(11):1364-71. PubMed ID: 11684952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.